Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact email@example.com.
Casting Light on an Underserved Population: Evidence Review of HIV Among Migrants in the EU/EEA
31 Pages Posted: 30 Mar 2021More...
HIV epidemics in the EU/EEA (European Union/European Economic Area ) are increasingly diverse in terms of transmission modes and people affected. This systematic search and review synthesises the evidence on vulnerable migrants living in this region (including but not limited to people with irregular status). Review findings show that many migrants carry a higher HIV burden than the general population. Of concern are high proportions of post-migration HIV acquisition (about 40% across various studies), a high risk of remaining undiagnosed or being diagnosed late and challenges in accessing and staying on treatment. Multi-level and intersecting factors were shown to reduce access to HIV services along the HIV continuum of care (PrEP, timely HIV testing, and access to treatment for irregular migrants). Ensuring equitable access to HIV prevention, testing and treatment services for all migrants at increased risk for HIV is needed to meet global targets for ending AIDS by 2030.
Funding Information: This study was funded through an Agreement for Performance of Work from UNAIDS (2019/959239/202466139).
Declaration of Interests: None declared.
Suggested Citation: Suggested Citation